Surgery Partners, Inc. SGRY
14.40
0.20
1.41%
as of 25 Sep
- Market cap
- $1.9B
- P/E
- 0.0×
Follow SGRY
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.64 | 0.46 | 0.59 | 0.84 | |
P/FCF ratio |
11.30 | 6.13 | 8.12 | 11.56 | |
P/Operating CF |
36.50 | 130.78 | 19.01 | 32.93 | |
P/B ratio |
0.70 | 0.49 | 0.63 | 0.88 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.69 | 1.51 | 1.64 | 1.86 | |
EV/EBITDA |
9.77 | 8.54 | 9.22 | 10.54 | |
EV/Operating CF |
22.09 | 18.08 | 19.79 | 21.65 | |
EV/FCF |
29.76 | 20.27 | 22.42 | 25.67 | |
Quick Ratio |
1.44 | 1.35 | 1.37 | 1.34 | |
Current Ratio |
1.95 | 1.86 | 1.87 | 1.88 | |
Net Debt/EBITDA |
23.91 | 32.58 | 19.59 | 22.34 | |
Debt/Assets |
46.60% | 46.18% | 45.60% | 44.84% | |
Debt/Equity |
1.21 | 1.20 | 1.18 | 1.13 | |
Asset Turnover |
0.42 | 0.42 | 0.41 | 0.42 | |
Operating CF/Net income |
(3.95) | (0.33) | (6.89) | (3.68) | |
Capex/Depreciation |
(0.55) | (0.42) | (0.15) | (0.50) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
4.28% | 4.85% | 2.68% | 2.73% | |
Intangible Assets out of Total Assets |
0.65 | 0.65 | 0.64 | 0.65 | |
Share Based Compensation of Revenue |
0.45% | 0.72% | (0.25%) | 0.32% | |
Graham Net Nets |
(1.77) | (2.52) | (1.95) | (1.34) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(4.17%) | (5.03%) | (4.01%) | (6.28%) | |
Free Cash Flow Yield |
8.85% | 16.32% | 12.32% | 8.65% | |
Revenue per Share |
6.59 | 6.32 | 6.96 | 6.46 | |
Operating CF per Share |
0.46 | 0.09 | 0.81 | 0.66 | |
Capex per Share |
(0.17) | (0.12) | (0.07) | (0.16) | |
Free Cash Flow per Share |
0.29 | (0.03) | 0.74 | 0.50 | |
Cash per Share |
1.68 | 1.42 | 1.89 | 1.60 | |
Shareholders Equity per Share |
24.08 | 24.13 | 24.62 | 24.70 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
24.08 | 24.13 | 24.62 | 24.70 | |
Free Cash Flow |
37.80 | (4.30) | 94.20 | 63.80 | |
Working Capital |
547.50 | 500.80 | 535.20 | 516.20 | |
Capital Expenditures |
(21.50) | (16.00) | (9.20) | (19.80) | |
Net Current Asset Value |
(3,822.00) | (3,861.70) | (3,837.70) | (3,702.40) | |
EV/EBIT |
14.03 | 12.20 | 13.16 | 14.22 | |
Capex to Sales |
0.03 | 0.02 | 0.01 | 0.02 | |
Net Profit Margin |
(1.77%) | (4.43%) | (1.69%) | (2.76%) | |
Price to Operating Income |
5.64 | 3.89 | 5.05 | 6.77 | |
| Other line items | |||||
Average Receivables |
589.85 | 587.00 | 590.65 | 561.10 | |
Average Payables |
175.05 | 166.80 | 208.70 | 172.70 | |
Average Inventory |
93.05 | 94.30 | 92.50 | 87.15 | |
Average Assets |
8,002.25 | 7,995.65 | 8,004.85 | 7,740.50 | |
Average Common Equity |
3,129.10 | 3,126.95 | 3,163.85 | 3,126.95 |
Columns are period end dates